Biocryst Pharmaceuticals (BCRX) Cash from Operations (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Cash from Operations came in at 61791000.0 in Q1 2026, down 124.56% YoY from 251635777.27 in Q1 2025, and down 121.16% on a QoQ basis from 291960000.0 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Cash from Operations (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Cash from Operations data on file, last reported at 61791000.0 in Q1 2026.
- Quarterly Cash from Operations fell 124.56% year-over-year to 61791000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 313095000.0 (up 1311.06% YoY) and the FY2025 annual result came in at 347369000.0, up 767.76% from the prior year.
- Cash from Operations retreated to 61791000.0 in Q1 2026, from 291960000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 291960000.0 in Q4 2025 to a low of 77800000.0 in Q1 2022.
- A 5-year average of 1378411.76 and a median of 19897000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations soared 5700.61% — and 2026, when it slumped 124.56%.
- Tracing BCRX's Cash from Operations over 5 years: stood at 23849000.0 in 2022, then soared by 62.61% to 8918000.0 in 2023, then jumped by 41.55% to 5213000.0 in 2024, then soared by 5700.61% to 291960000.0 in 2025, then plunged by 121.16% to 61791000.0 in 2026.
- The last three Cash from Operations figures came in at 61791000.0 (Q1 2026), 291960000.0 (Q4 2025), and 41624000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 104.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.34 Mn |
| Jun 30, 2026 | 104.34 Mn |
| Mar 31, 2026 | -61.79 Mn |
| Mar 31, 2026 | -61.79 Mn |
| Dec 31, 2025 | 291.96 Mn |
| Dec 31, 2025 | 291.96 Mn |
| Sep 30, 2025 | 41.62 Mn |
| Sep 30, 2025 | 41.62 Mn |
| Jun 30, 2025 | 41.30 Mn |
| Jun 30, 2025 | 41.30 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Dec 31, 2024 | -5.21 Mn |
| Dec 31, 2024 | -5.21 Mn |
| Sep 30, 2024 | 8.25 Mn |
| Sep 30, 2024 | 8.25 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Mar 31, 2024 | -53.68 Mn |
| Mar 31, 2024 | -53.68 Mn |